Rajinder Mahay, MD
Internal Medicine · Granite City, ILNPI 1669490421
Payments from drug & device makers
Across 251 payments — averaging $17.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$946
- AbbVie$816
- Novo Nordisk$454
- GSK$294
- Astellas Pharma US Inc$215
- Pfizer$174
- plus $2K from 26 others
What the payments were for
- Food & beverage$4,31498%
- Education$1002%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 51 | $946 |
| AbbVie(2 entities) | 54 | $816 |
| Novo Nordisk | 27 | $454 |
| GSK | 18 | $294 |
| Astellas Pharma US Inc | 8 | $215 |
| Pfizer | 10 | $174 |
| Lilly USA, LLC | 10 | $171 |
| Amarin Pharma, Inc. | 7 | $130 |
| Sumitomo Pharma America, Inc. | 6 | $122 |
| Abbott | 6 | $96 |
| Cardiac Dimensions, Inc. | 1 | $90 |
| Sanofi-aventis U.S. LLC | 5 | $89 |
| Boehringer Ingelheim | 5 | $87 |
| Johnson & Johnson | 5 | $83 |
| Amgen | 4 | $72 |
| Teva Pharmaceuticals USA, Inc. | 4 | $64 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $64 |
| Merck | 3 | $56 |
| Sunovion Pharmaceuticals Inc. | 3 | $53 |
| Kowa Pharmaceuticals America, Inc. | 3 | $45 |
| Biohaven Pharmaceuticals, Inc. | 2 | $43 |
| Genentech USA, Inc. | 2 | $32 |
| Phathom Pharmaceuticals, Inc. | 2 | $31 |
| Exact Sciences | 2 | $30 |
| Novartis | 2 | $29 |
| Optinose US, Inc. | 1 | $24 |
| Acadia Pharmaceuticals Inc | 1 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Assertio Therapeutics, Inc. | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Bayer | 1 | $13 |
| Esperion Therapeutics, Inc. | 1 | $13 |
How this compares
$4,414 in reported general payments places this provider in the 90th percentile of 5,182 internal medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 195 | $283,870 |
| FarxigaDapagliflozin Propanediol | 166 | $157,904 |
| JardianceEmpagliflozin | 133 | $157,605 |
| EliquisApixaban | 99 | $101,809 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 94 | $85,004 |
| XareltoRivaroxaban | 55 | $51,690 |
| Breo ElliptaFluticasone/Vilanterol | 62 | $37,334 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 32 | $36,798 |
| MounjaroTirzepatide | 33 | $35,962 |
| Tresiba Flextouch U-100Insulin Degludec | 64 | $32,071 |
| LinzessLinaclotide | 39 | $30,140 |
| MyrbetriqMirabegron | 37 | $29,835 |
| SymbicortBudesonide/Formoterol Fumarate | 93 | $28,312 |
| TrulicityDulaglutide | 27 | $28,091 |
| Spiriva HandihalerTiotropium Bromide | 40 | $27,645 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $454 | $283,870195 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $946 | $271,219353 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $87 | $178,879157 claims |
| PfizerEliquis | $174 | $101,80999 claims |
| GSKBreo Ellipta, Trelegy Ellipta | $294 | $74,13294 claims |
| Lilly USA, LLCMounjaro, Trulicity | $171 | $64,05360 claims |
| Johnson & JohnsonXarelto | $83 | $51,69055 claims |
| MerckJanuvia, Janumet | $56 | $43,68333 claims |
| AbbVieLinzess, Savella | $816 | $36,36851 claims |
| Astellas Pharma US IncMyrbetriq | $215 | $29,83537 claims |
| Sanofi-aventis U.S. LLCLantus | $89 | $3,65225 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,182 internal medicine providers in Illinois.
Other internal medicine in Granite City
- Dennis LevinsonChicago$25.3M
- Mary BrownRockford$16M
- Andrew BartlettChampaign$4.1M
- Danny SugimotoChicago$4M
- Peter O DonnellChicago$3.9M
- Daniel CatenacciChicago$3.5M
- Jeffrey GeohasEvanston$2.3M
- Patricia WalshChicago$2.1M
- Merle DiamondChicago$1.7M
- Yoko MomoyamaLombard$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.